Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Kane Biotech Inc.
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
13 mars 2025 08h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review...
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel
11 mars 2025 08h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech”) announces that it has concluded a three-year distribution agreement with Best Buy...
Kane Biotech Announces Second and Final Closing of Private Placement Offering
19 févr. 2025 08h30 HE
|
Kane Biotech Inc.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the...
Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology
21 janv. 2025 08h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday, January 23, 2025 at 4:15pm Eastern...
Kane Biotech Announces First Closing of Private Placement Offering and Extension of Private Placement Offering
20 janv. 2025 08h30 HE
|
Kane Biotech Inc.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”,...
Kane Biotech Announces $3,000,000 Private Placement Offering
03 déc. 2024 08h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it intends to undertake a non-brokered...
Kane Biotech Announces Third Quarter 2024 Financial Results
28 nov. 2024 16h15 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its third quarter 2024 financial results. ...
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
27 nov. 2024 08h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech” or “Kane”) announces today that BioStem Technologies Inc....
Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024
21 nov. 2024 16h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will release its third quarter 2024 financial results after market close on...
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
14 nov. 2024 13h10 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its...